Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Ford Investor Services, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BIOLASE Inc Announces NewTom BIOLASE VG3 Panoramic Oral X-Ray System Receives FDA Clearance

Thursday, 16 May 2013 09:10am EDT 

BIOLASE Inc announced that the U.S. Food and Drug Administration (the FDA) has cleared the NewTom BIOLASE VG3 (VG3) digital panoramic, cephalometric, and tomographic extra-oral X-ray system which BIOLASE will market and distribute in the U.S. for $50,000 to $120,000. BIOLASE is the exclusive distributor of NewTom digital imaging products for the dental market in the U.S. and Canada. The VG3 is a significant complement to the ultra-high performance full field of view (FOV) provided by the NewTom VGi, which is currently distributed by BIOLASE. The new VG3 is a truly modular hybrid 2D/3D system that can start as a digital 2D panoramic X-ray system, which replaces traditional film-based panoramic units, that can be upgraded at any time to add either a cephalometric sensor and software, necessary for orthodontics and diagnosing head, jaw, and facial pain, and/or 3D cone-beam-computed-tomography (CBCT) with an 11" x 8" FOV, used for implants, endodontics, gum disease, sinus problems, and oral and maxillofacial surgery. The VG3 comes equipped with NewTom's NNT 4.0 imaging analysis software and incorporates NewTom's patented Safebeam technology which emits the lowest possible dosage of radiation. Safebeam technology automatically adjusts the radiation dosage and continuously monitors systems operations thereby eliminating the possibility of unnecessary exposures making it the safest available for patients and staff. 

Company Quote

-0.01 -0.51%
11 Jul 2014